<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00635765</url>
  </required_header>
  <id_info>
    <org_study_id>C2L-OCT-01 PR-302</org_study_id>
    <nct_id>NCT00635765</nct_id>
  </id_info>
  <brief_title>Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients</brief_title>
  <official_title>Open Label Extension Study Evaluating the Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, Administered Intra Muscularly Every 6, 5 or 4 Weeks in Acromegalic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ambrilia Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ambrilia Biopharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety profile of C2L-OCT-01 PR for up to an
      additional 96-week period in acromegalic patients who completed the C2L-OCT-01 PR-301 study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess, for up to an additional 96 weeks, the safety profile of C2L-OCT-01 PR administered intra muscularly every 6, 5 or 4 weeks in patients who have completed the C2L-OCT-01 PR-301 study.</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the percentage of patients who remain with controlled mean GH and normal (gender- and age-matched values) IGF-1 serum concentrations.</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare plasma concentrations of C2L-OCT-01 PR.</measure>
    <time_frame>First 6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Acromegaly</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C2L-OCT-01 PR 30 mg</intervention_name>
    <description>Administered by deep IM (gluteus) on Day 1. Beginning on Day 42, drug injection frequency (6, 5 or 4 weeks) and dose modification/adjustment will be allowed for every 3 drug injections based on the mean serum GH and clinical symptoms obtained at the last visit of study C2L-OCT-01 PR-301 and during the course of this study.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢Subjects who have completed the 24-week C2L-OCT-01 PR-301 study

        Exclusion Criteria:

          -  Women of childbearing potential who are not taking adequate contraception or who are
             pregnant or lactating

          -  Subjects who have experienced any clinically significant adverse event related to
             study medication in C2L-OCT-01 PR-301 study

          -  Subjects with uncontrolled Diabetes type II

          -  Subjects with signs or symptoms related to a tumor compression of the optical chiasm

          -  Subjects with symptomatic cholelithiasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphael Naudin, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ambrilia Biopharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Republican Centre for Medical Rehabilitation and Water-therapy</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Altalanos Orvostudomanyi</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institue of Endocrinology &quot;C.I Parhon&quot; Bucharest</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Endocrinology, University Clinical Center</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna Nemocnica s Poliklinkow Bratislava</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V.P. Komisarenko Institute of Endocrinology and Metabolism, AMS Ukraine</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Hungary</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2008</study_first_submitted>
  <study_first_submitted_qc>March 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2008</study_first_posted>
  <last_update_submitted>June 3, 2009</last_update_submitted>
  <last_update_submitted_qc>June 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Bonabes de Rouge, M.D./Senior Executive Vice-President &amp; Chief Scientist Officer</name_title>
    <organization>Ambrilia Biopharma, Inc.</organization>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

